CS202484B1 - Method of evolving basis of alkaloids ergotoxine type from their salts - Google Patents
Method of evolving basis of alkaloids ergotoxine type from their salts Download PDFInfo
- Publication number
- CS202484B1 CS202484B1 CS300279A CS300279A CS202484B1 CS 202484 B1 CS202484 B1 CS 202484B1 CS 300279 A CS300279 A CS 300279A CS 300279 A CS300279 A CS 300279A CS 202484 B1 CS202484 B1 CS 202484B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- salts
- alkaloids
- type
- ergotoxine
- alkaloid
- Prior art date
Links
- 229930013930 alkaloid Natural products 0.000 title claims description 15
- 150000003839 salts Chemical class 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 2
- -1 alkaloid salt Chemical class 0.000 claims description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UJYGDMFEEDNVBF-UHFFFAOYSA-N ergocornin Chemical compound C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- ORBSYPFBZQJNJE-MPKXVKKWSA-N (6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxylic acid Chemical class C1=CC([C@H]2C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ORBSYPFBZQJNJE-MPKXVKKWSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- YDOTUXAWKBPQJW-UHFFFAOYSA-N alpha-Ergocryptinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-UHFFFAOYSA-N 0.000 description 1
- YDOTUXAWKBPQJW-NSLWYYNWSA-N alpha-ergocryptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-NSLWYYNWSA-N 0.000 description 1
- 229950001817 alpha-ergocryptine Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- XLMJRFCCCWFQRE-SJRQCXNHSA-N ecboline Chemical compound C([C@H]1[C@]2(O)O3)CCN1C(=O)CN2C(=O)[C@]3(C(C)C)NC(=O)[C@@H](CN(C)[C@@H]1C2)C=C1C1=C3C2=CNC3=CC=C1 XLMJRFCCCWFQRE-SJRQCXNHSA-N 0.000 description 1
- HEFIYUQVAZFDEE-MKTPKCENSA-N ergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@@H]1C=C2C=3C=CC=C4NC=C(C=34)C[C@H]2N(C)C1)C(C)C)C1=CC=CC=C1 HEFIYUQVAZFDEE-MKTPKCENSA-N 0.000 description 1
- HEFIYUQVAZFDEE-UHFFFAOYSA-N ergocristinine Natural products N12C(=O)C(C(C)C)(NC(=O)C3C=C4C=5C=CC=C6NC=C(C=56)CC4N(C)C3)OC2(O)C2CCCN2C(=O)C1CC1=CC=CC=C1 HEFIYUQVAZFDEE-UHFFFAOYSA-N 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Vynález se týká nového způsobu izolaoe bází alkaloidů ergotoxinového typu /ergokristin, ergokornin, ergokryptin oO i jb / z jejich edičních solí s minerálními kyselinami. Způsob umožňuje získávat z těchto solí jednodušeji a ve vyšším výtěžku než dosud výše uvedená látky a jejich libovolné směsi, jako i rozkládat soli hydrogenováných alkaloidů tohoto typu.The present invention relates to a novel process for the isolation of ergotoxin-type alkaloids (ergocristin, ergocornin, ergocryptine 10 and jb) from their mineral acid-editing salts. The process makes it possible to obtain from these salts more easily and in a higher yield than the above-mentioned substances and any mixtures thereof, as well as to decompose salts of hydrogenated alkaloids of this type.
Alkaloidy typu ergotoxinu jsou získávány z přírodních surovin pro přípravu farmaceutických preparátů. Jejich izolace je nákladná a zdlouhavá. Zjednodušení jednoho z výrobních stupňů spojené se zvýšením výtěžku proto představuje významný ekonomický přínos. Dosavadní způsoby výroby těchto látek řešily problém rozkladu jejich solí následovně : sůl byla rozmíchána spolu s příslušným množstvím hydrogenuhličitanu sodného ve vodném roztoku amoniaku. Takto vzniklá vodná suspenze byla potom extrahována vhodnými organickými rozpouštědly.Alkaloids of the ergotoxin type are obtained from natural raw materials for the preparation of pharmaceutical preparations. Their insulation is costly and time consuming. Therefore, simplifying one of the production steps associated with an increase in yield represents a significant economic benefit. The prior art processes for solving these compounds have solved the problem of decomposing their salts as follows: the salt was mixed together with an appropriate amount of sodium bicarbonate in aqueous ammonia solution. The resulting aqueous suspension was then extracted with suitable organic solvents.
Spojené organická podíly byly potom vytřepány vodou, zahuštěny na vhodný objem a zfiltrovány přes vrstvu kysličníku hlinitého. Filtrát byl potom odpařen do sucha. Během několikanásobné extrakce docházelo nutně ke ztrátám na surovině strháváním části organické fáze do vodné vrstvy - tyto ztráty jsou procenticky malé, vzhledem k vysoké ceně zpracovávané suroviny však nezanedbatelné. Alkaloidy ergotoxinového typu podléhají v roztoku snadno epimerizaci, vzniklé pravotoČivé enantiomery jsou farmakologicky méně účinné a představují v surovině nevítaný balast. Vzhledem ke značné časové náročnosti opakované extrakce do202 484The combined organics were then shaken with water, concentrated to an appropriate volume, and filtered through a pad of alumina. The filtrate was then evaporated to dryness. During the multiple extraction, there was necessarily a loss of raw material by entraining part of the organic phase into the aqueous layer - these losses are small in percentage, but due to the high cost of the processed raw material, they are not negligible. Erotoxin-type alkaloids are readily epimerized in solution, the dextrorotatory enantiomers formed are less pharmacologically active and are unwanted ballast in the raw material. Due to the considerable time required for repeated extraction up to 202 484
202 484 chází ke zřetelnému zvýšení obsahu popsaných bezcenných izomerů v surovině.202,484 there is a marked increase in the content of the described worthless isomers in the feedstock.
Tyto nevýhody odstraňuje postup, který je předmětem vynálezu. Adiční sůl alkaloidů s příslušnou minerální kyselinou se rozloží za teploty místnosti plynným amoniakem v prostředí ethanolu, methanolu, acetonu, ethylacetátu, benzenu nebo etheru, s výhodou chloroformu, nerozpustná amonná sůl se oddělí od roztoku báze alkaloidu filtrací, přebytečný amoniak se vypudí záhřevem, roztok se přičistí ohromatografií na sloupci kysličníku hlinitého a odpaří do sucha, Popsaný způsob uvolňování bází alkaloidů z jejich solí lze použít k rozkladům libovolných adiěních solí alkaloidů s kyselinami. Podmínkou je nerozpustnost amonné soli dané kyseliny a naopak rozpustnost báze příslušného alkaloidu v daném rozpouštědle. Metoda je použitelná i pro rozklady solí hydrogenovaných alkaloidů /derivátů kyseliny 9,10-dihydro-D-lysergové/.These disadvantages are overcome by the process of the present invention. The alkaloid addition salt with the appropriate mineral acid is decomposed at room temperature with gaseous ammonia in ethanol, methanol, acetone, ethyl acetate, benzene or ether, preferably chloroform, the insoluble ammonium salt is separated from the alkaloid base solution by filtration, the excess ammonia is expelled by heating. The method of liberating alkaloid bases from their salts can be used to decompose any acid addition of alkaloid salts. The condition is the insolubility of the ammonium salt of the acid and, conversely, the solubility of the alkaloid base in the solvent. The method is also applicable to decomposition of salts of hydrogenated alkaloids (9,10-dihydro-D-lysergic acid derivatives).
Pří klad 1 g surového hydrofosforečnanu ergokristinia bylo rozmícháno za teploty místnosti v 80 ml chloroformu. Po zhruba 5 minutách zavádění plynného amoniaku byla směs zahřáta k varu. Po vypuzení přebytečného amoniaku směs ochlazena, fosforečnan amonný odfiltrován, filtrát přečištěn průchodem vrstvou kysličníku hlinitého a odpařen do sucha.Example 1 g of crude ergocristinium hydrogen phosphate was stirred at room temperature in 80 ml of chloroform. After about 5 minutes of introduction of ammonia gas, the mixture was heated to boiling. After expulsion of the excess ammonia, the mixture was cooled, the ammonium phosphate was filtered off, the filtrate was purified by passing through a layer of alumina and evaporated to dryness.
Příklad 2 g surové směsi hydrofosforečnanu ergocorninia a ergokrýptiniá bylo rozmícháno v 70 ml ethylacetátu a byl zaváděn plynný amoniak. Po vypuzení přebytečného amoniaku směs ochlazena, přefiltrována přes vrstvu křemeliny, filtrát přečištěn průchodem vrstvou kysličníku hlinitého a zahuštěn. Vyloučená krystalická báze odfiltrována a prorayta vychlazeným ethylacetátem.Example 2 g of a crude mixture of ergocorninium hydrophosphate and ergocryptinium was stirred in 70 ml of ethyl acetate and ammonia gas was introduced. After expulsion of the excess ammonia, the mixture was cooled, filtered through a pad of diatomaceous earth, the filtrate was purified by passing through a pad of alumina and concentrated. The precipitated crystalline base was filtered off and washed with cold ethyl acetate.
Příklad 3 g methansulfonanu dihydroergotoxinia bylo rozmícháno za teploty místnosti v 50 ml chloroformu. Po zhruba 5 minutách zavádění plynného amoniaku byla směs zahřáta k varu. Po vypuzení přebytečného amoniaku směs ochlazena, methansulfonan amonný odfiltrován a filtrát odpařen do sucha.Example 3 g of dihydroergotoxinium methanesulfonate was stirred at room temperature in 50 ml of chloroform. After about 5 minutes of introduction of ammonia gas, the mixture was heated to boiling. After expulsion of the excess ammonia, the mixture was cooled, the ammonium methanesulfonate was filtered off and the filtrate was evaporated to dryness.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS300279A CS202484B1 (en) | 1979-05-02 | 1979-05-02 | Method of evolving basis of alkaloids ergotoxine type from their salts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS300279A CS202484B1 (en) | 1979-05-02 | 1979-05-02 | Method of evolving basis of alkaloids ergotoxine type from their salts |
Publications (1)
Publication Number | Publication Date |
---|---|
CS202484B1 true CS202484B1 (en) | 1981-01-30 |
Family
ID=5368836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS300279A CS202484B1 (en) | 1979-05-02 | 1979-05-02 | Method of evolving basis of alkaloids ergotoxine type from their salts |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS202484B1 (en) |
-
1979
- 1979-05-02 CS CS300279A patent/CS202484B1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU776557A3 (en) | Method of preparing optically active anthracyclinones | |
Inubushi et al. | Structures of Montanine, Coccinine, and Manthine1 | |
US3704233A (en) | O-acyl-lysergols and process for preparing them | |
DD264430A5 (en) | PROCESS FOR THE PREPARATION OF 2-BROM-2-ERGOKRYPTIN | |
Spenser | A synthesis of harmaline | |
Ayer et al. | The structure of lycodine | |
KOBAYASHI et al. | Alkaloids of the amaryllidaceae. A new alkaloid, sanguinine, from Lycoris sanguinea Maxim. var. Kiushiana Makino, and pretazettine from Lycoris radiata Herb. | |
CH520680A (en) | Ergot derivs andrenolytics | |
US4088647A (en) | Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same | |
Schwarz et al. | THREE MINOR ALKALOIDS OF GELSEMIUM SEMPERVIRENS AIT. | |
CS202484B1 (en) | Method of evolving basis of alkaloids ergotoxine type from their salts | |
Danieli et al. | Aspidosperma alkaloids. Conversion of tabersonine into vindoline | |
SU645581A3 (en) | Method of obtaining d-2-halogen-6-methyl-8-cyanomethyl- or d-2-halogen-6-methyl-8-carboxamidomethylergolines | |
US3583992A (en) | 1-methyl-d-lysergic acid-dihydroxy-alkyl-amides | |
SU1207396A3 (en) | Method of isolating vincristine | |
US3799933A (en) | Method of preparing new indolic derivatives usable for synthesizing dextro-rotary vincamine | |
US4697017A (en) | Process for the preparation of 2-bromo-α-ergocryptine | |
DE3205169A1 (en) | NEW ERGOL DERIVATIVES, THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS | |
US3888865A (en) | Process for the preparation of eburnamonines | |
Niwa et al. | Chemical studies on nitrogen heterocyclic skeleton of the Daphniphyllum alkaloids | |
Teulade et al. | Carbon-nitrogen bond formation in cyclisations by deoxygenation, thermolysis, or photolysis of phenylimidazo [1, 2-a] pyridine systems: access to pyrido [1′, 2′: 1, 2] imidazo [4, 5-b] indoles | |
Falkiner et al. | Isolation of unstable alkaloids from Erythrophleum chlorostachys (Leguminosae) | |
US4070358A (en) | Process for the preparation of diindole alkaloids or of the acid addition salts thereof | |
DE2021706C2 (en) | Process for the production of peptide-like ergot alkaloids | |
US2833771A (en) | Process for the preparation of |